$RGC Small Cap Bioscience/Healthcare Company - ASD
Post# of 24966
(Total Views: 163)
Posted On: 12/10/2022 7:12:13 AM
$RGC Small Cap Bioscience/Healthcare Company - ASD, ADHD and COV19 Treatments
Regencell Bioscience Holdings Limited (Nasdaq: RGC) - an early-stage bioscience company that focuses on the Research and Development and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and treatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalisation.
https://www.morningstar.com/news/business-wir...ses-by-ceo
Regencell Bioscience Holdings Limited (Nasdaq: RGC) - an early-stage bioscience company that focuses on the Research and Development and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and treatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalisation.
https://www.morningstar.com/news/business-wir...ses-by-ceo
(0)
(0)Scroll down for more posts ▼